Related Experiment Videos
Acute promyelocytic leukemia: a curable disease
F Lo Coco1, C Nervi, G Avvisati
1Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy.
Leukemia
|December 9, 1998
Summary
Advances in Acute Promyelocytic Leukemia (APL) treatment were discussed, focusing on molecular mechanisms, novel therapies like arsenicals, and clinical trial results integrating all-trans retinoic acid (ATRA). Discussions also covered APL heterogeneity and special patient populations.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- The Second International Symposium on Acute Promyelocytic Leukemia (APL) convened in Rome (November 1997) to review progress since 1993.
- Focus was on significant advances in APL biology and treatment strategies.
Framework:
- Explored molecular mechanisms of leukemogenesis and retinoid response/resistance.
- Discussed biologic and therapeutic effects of arsenicals and novel retinoids.
- Characterized APL heterogeneity (morphological, cytogenetic, immunophenotypic).
Implementation:
- Presented updated results from large cooperative clinical trials combining all-trans retinoic acid (ATRA) and chemotherapy.
- Integrated molecular assessment of treatment response into clinical trial data.
- Debated optimal frontline treatment strategies for APL.
Implications:
- Addressed APL management in specific groups: elderly and pediatric patients.
- Evaluated the role of bone marrow transplantation in APL treatment.
- Discussed the prognostic value of molecular monitoring in APL.